NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Free Report) – Equities researchers at HC Wainwright dropped their FY2027 earnings estimates for shares of NewAmsterdam Pharma in a note issued to investors on Thursday, August 6th. BMO Capital Markets started coverage on NewAmsterdam Pharma in a report on Monday, July 20th. NewAmsterdam Pharma Stock Up 0.9%NAMS opened at $27.67 on Friday. NewAmsterdam Pharma Company Profile(Get Free Report)NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. Featured StoriesReceive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.